Answers are grounded in this paper and cite their sources.
Phase 2 study shows limited effectiveness of drugs in treating metastatic pancreatic ductal adenocarcinoma, suggesting specific biomarkers for patient selection.
Azacitidine plus pembrolizumab demonstrated limited clinical activity in second line, locally advanced or metastatic PDAC. Biomarker analysis suggests higher baseline CD8+ T-cell infiltration and lower proliferative index may identify patients more likely to benefit. (NCT03264404).
No takes yet. Share an insight, caveat, or question.
Safyan et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: